Persona / Patient
Patients
You saw the commercial. Before you ask your doctor about it, see what the trial data says and what the manufacturer spent to reach you.
Section 01 / Why this exists
Ask your doctor about the ad evidence.
You saw the commercial. Here's what it didn't tell you: in nine months Wegovy spent $316M on consumer ads and scored 72/100 on clinical evidence. Zepbound spent $131M and scored 89/100. SpendSight prints the ad budget right next to the evidence score, so you can tell whether a drug is better or just advertised more, before your ten minutes with the doctor start.
Free for patients
No manufacturer money
Every figure cited
02
The gap we measure
$699M
spent on consumer ads by four GLP-1 brands in nine months, none of it required to mention comparative efficacy.
2.4x
Wegovy outspent Zepbound on advertising while trailing it by 17 Quality Score points.
1.02 vs 0.23
the best and worst Value Ratio in the same drug class. Marketing budgets and clinical value move independently.
Sources: MediaRadar DTC advertising data (Jan to Sep 2025), FDA OpenFDA, ClinicalTrials.gov, SEC filings. Figures reproduced in the live audit.
03
Who reads this label
Persona / Clinician
Healthcare providers
Patients arrive pre-sold by ad campaigns. Answer with the same brand names and one objective score, cited to its sources, in the exam room.
Persona / Researcher
Researchers
Study the relationship between promotion and evidence across 500+ drugs with a documented, reproducible scoring method.
04
Product monograph
Six instruments, one discipline. Every claim below has a working counterpart in the live audit, and every figure carries its citation.
No.
Instrument
What it does
Proof in demo
01
Quality Scores
Scores each drug 0 to 100 from clinical trial efficacy, patient outcomes, FDA status, and safety profile. No marketing input touches the number.
02
Spend Transparency
Shows what each manufacturer spends on direct-to-consumer advertising, month by month, from MediaRadar tracking data.
03
Value Ratio
Divides the Quality Score by millions of ad dollars. High ratios earn their reputation; low ratios buy it.
04
Spend Alerts
Flags when a tracked drug's advertising pattern breaks trend, so you know when the push starts before the prescriptions follow.
05
Telehealth Connect
Compares vetted telehealth prices for the same prescription, with our referral commission disclosed on every listing.
06
Source Citations
Links every data point to FDA OpenFDA, ClinicalTrials.gov, MediaRadar, or SEC filings. If we cannot cite it, we do not print it.
05
Quality Score composition
Each drug's score is a weighted composite of four evidence classes. The weights are fixed, published, and identical for every drug.
Clinical trial efficacy
40%
Patient outcomes
25%
FDA approval status
20%
Safety profile
15%
The four weights sum to 100. Advertising spend never enters the score; it is reported beside it. SpendSight is a data tool, not medical advice. Talk to your clinician before changing any medication.
06
Price
$0.00
per patient, per month, permanently
- Quality Scores and comparisonsincluded
- Ad spend audits and Spend Alertsincluded
- Source citations on every figureincluded
- Telehealth price comparisonincluded
How we stay free. When you choose to fill a prescription through a telehealth
partner we list, that partner pays us a referral commission. We disclose it on every listing,
and it never influences a Quality Score. We take no money from drug manufacturers.
07
Frequent questions
Where does SpendSight get its data?
We aggregate public sources: MediaRadar for advertising spend, FDA OpenFDA for approval and safety records, ClinicalTrials.gov for efficacy results, and SEC filings for manufacturer disclosures. Every displayed figure links back to its source.
Is SpendSight medical advice?
No. SpendSight organizes public data so you can have a better-informed conversation with your clinician. Always consult a physician before starting, stopping, or switching a medication.
How is the Quality Score calculated?
The score combines clinical trial efficacy (40%), patient outcomes (25%), FDA approval status (20%), and safety profile (15%). The weights are fixed and published in section 05, and advertising spend never enters the calculation.
Is SpendSight really free?
Yes, free for patients with no credit card and no trial clock. We earn a disclosed referral commission when users choose to fill a prescription through a telehealth partner. Manufacturers cannot pay us, sponsor us, or affect a score.
Section 08 / Request access
Get the label before the launch.
SpendSight is pre-launch and the waitlist is open. Join it and we will notify you the day the audit goes live, starting with the GLP-1 class you can inspect in the demo today.
Fields marked * are required. We store your entry to notify you at launch and for nothing else.